Is 7-OH Addictive? Why Dependence Builds so Fast

What 7-OH actually is

7-hydroxymitragynine is one of the alkaloids in the kratom plant, and it is a minor one. NIDA puts it at under 2 percent of the total alkaloid content of the leaf. The products on shelves are concentrated or synthesized to reach a dose the plant itself never delivers, which is why the leaf and the concentrate behave so differently. If you want the composition side of that in full, we cover what concentrated 7-OH is, next to the leaf separately.

Why it is sold the way it is

7-OH reaches buyers as tablets, gummies, drink mixes and shots, sold at gas stations, smoke shops and online. That retail position is the whole problem in miniature, because it reads as a consumer product rather than an opioid. The Drug Enforcement Administration opened a temporary scheduling process for concentrated 7-OH in July 2026, so current availability is a reflection of where regulation has got to, not a signal about safety.

Why dependence forms so fast

Three things stack up: what the molecule does at the receptor, how often it gets taken, and the fact that nobody is supervising either.

What the receptor activity does

7-OH is a mu-opioid receptor agonist. That is the same receptor family morphine, oxycodone and fentanyl act on, and it is why the body responds to 7-OH with the same adaptations it makes to a prescription opioid. The FDA's scientific assessment of 7-OH put its potency at 4.4 to 13 times that of morphine in animal work, and found it depressed breathing at more than three times morphine's potency. The FDA has also been explicit that 7-OH products are opioids and none has an approved medical use.

The self-administration evidence

The clearest evidence that 7-OH carries genuine addiction liability comes from animal research rather than from how people describe it. In a study published in Addiction Biology, 7-OH substituted for morphine in a rat self-administration paradigm, dose for dose, and maintained intravenous self-administration on its own. Mitragynine, the alkaloid that dominates the leaf, did not do either. Self-administration is the standard laboratory measure of whether a drug is reinforcing, so that result puts 7-OH in a different category from the plant it is extracted from.

Dosing frequency, and nobody setting the interval

A prescriber writing for an opioid sets a dose and an interval, and the pharmacy counts the tablets. With 7-OH there is no interval, no ceiling and no one watching. Men commonly describe starting at one dose in the morning and arriving at four or five a day inside a month, because each time the effect fades sooner they take another. Tolerance is the body adapting to a repeated dose, and frequency is the lever that moves it fastest.

Tolerance, dependence and addiction are three different things

Tolerance means the same dose does less than it used to. Physical dependence means the body has adjusted to the drug being present, so its absence produces symptoms. Addiction, clinically a substance use disorder, is the pattern of continued use despite harm, alongside loss of control over it. They usually arrive in that order, and the middle one is the part people misread. The evidence that dependence on 7-OH is physical rather than a matter of resolve is that stopping produces opioid-type withdrawal, which is documented in the clinical case literature and described by NIDA. We compare how 7-OH withdrawal differs from kratom leaf withdrawal in its own guide rather than here.

Who this tends to affect

The population reaching for these products is wider than it was, and the poison centre data is the clearest read on it. The Centers for Disease Control and Prevention reported that kratom-related reports to United States poison centres rose from 258 in 2015 to 3,434 in 2025, an increase of about 1,200 percent over the decade, drawn from the National Poison Data System. In the men Guiding Road works with, the route in is rarely a search for an opioid. It is a man working long hours who wanted something for energy, or someone who had come off prescription pain medication and found a product that felt like it took the edge off. He is often the last person in his household to describe what is happening as dependence, which is why families tend to start looking for answers first.

Common myths about 7-OH

Myth: it is sold over the counter, so it cannot be addictive

Where a product is sold says nothing about how it acts. The FDA describes 7-OH products as opioids and has recommended scheduling action on the concentrated form. Shelf position is a regulatory lag, not a pharmacological verdict.

Myth: needing it to feel normal means it is working

Needing a dose to feel level is the description of physical dependence, not of a drug doing its job. NIDA's account of the receptor activity is what explains the feeling: the body has adapted to the drug being present, and baseline has moved. The dose that once produced an effect is now the dose that prevents one being absent.

Myth: quitting is a matter of willpower

Opioid-type dependence is assessed and treated at a defined level of care, and the American Society of Addiction Medicine's National Practice Guideline for the Treatment of Opioid Use Disorder treats the decision about how to stop as a clinical one. A man who has tried three times and stopped on day two each time has learned something about the drug, not about his character.

When to reach out for help

The point worth acting on is earlier than most people think. If the dose has been climbing, if a day without it is being planned around, or if stopping has been attempted and abandoned more than once, that is a conversation worth having with a professional rather than a problem to outlast. Guiding Road does not provide detox on site. The admissions team coordinates a detox bed with a medical partner, which matters with an opioid-type dependence because the first days are the ones people stop on. Our guide to medically supervised detox, coordinated with a partner sets out how that is arranged. Treatment after that takes more than one form. Medication for opioid use disorder, using FDA-approved medications, has strong clinical evidence behind it and is one route. Guiding Road's own program is abstinence-based and 12-step-immersive, combining individual and group therapy with trauma-focused care and the local recovery community. Which fits a particular man depends on his history, and it is the kind of thing the admissions team can think through with a family. For a route that is not tied to any one provider, SAMHSA runs a free, confidential National Helpline on 1-800-662-4357, available 24 hours a day.

Signs it is time to talk to someone

• The dose has gone up, or the gap between doses has shortened.
• A day is being organised around having the product available.
• Stopping has been tried and abandoned more than once.
• Work, sleep or relationships have started to move around the use.
• Other substances are in the picture, particularly alcohol, benzodiazepines or another opioid.